Securities Regulation Daily Wrap Up, IPO TRACKER—Four California drug makers begin public trading, (Aug 11, 2026)
Organizations Mentioned:1776 Acquisition Corp. | ARC Group Securities Acquisition I | Attovia Therapeutics, Inc. | BOA Acquisition Corp. II | BlossomHill Therapeutics, Inc. | Braveheart Bio, Inc. | Danneskjold and Galt Acquisition Co. | Eaglesky Acquisition Corp. | Gravity Acquisition Corp. | Inflection Point Acquisition Corp. VIII | JATT III Acquisition Corp. | KiNRG, Inc. | Latigo Biotherapeutics, Inc. Pinnacle Acquisition Corp. | Lucens Capital Acquisition Corp. I | Luminous Acquisition | OceanLight Acquisition Corp. | Rainier Acquisition Corp. | Southport Acquisition Corp. II | TCGX Acquisition Corp. | Ticketplus Ltd. | Uh Orlando Sub REIT, LLC | Zensitive Holding Ltd.
A snapshot of the week’s IPO activity, including completed deals, new preliminary filings and IPO withdrawals.
What had been a relatively quiet year for the pharmaceutical prep (SIC 2834) and biological products (SIC 2836) industries took a turn last week as four California-headquartered drug makers went public. Three of them—BlossomHill Therapeutics, Braveheart Bio, and Latigo Biotherapeutics—are SIC 2834 companies. Their debuts represented one-fourth of that sector’s 12 IPOs so far this year. Attovia Therapeutics completed the sixth deal by an SIC 2836 company in 2026. The developer of treatments for immune-mediated diseases raised $289 million in its offering. Entertainment technology company Ticketplus also began trading last week, becoming the first Chilean new issuer in the U.S. since 2014. The chair of Ticketplus retained control of the company with a 62 percent share of all voting rights. With five new blank check deals in the week, SPACs now account for 140 of 2026’s 226 IPOs to date. The latest offerings were for ARC Group Securities Acquisition I, BOA Acquisition II, OceanLight Acquisition, Pinnacle Acquisition, and TCGX Acquisition.
New registrants. The week’s activity included 12 new registrations, one of which was filed by KiNRG, an early-stage company that is developing hydrothermal reactor projects to generate electricity without combusting fossil fuels. Following its acquisition of TRINITY Group Construction in April, the company’s focus is now on the construction of data centers and delivering off-the-grid energy. Hong Kong-based holding company Zensitive filed plans for a $25 million listing on the Nasdaq Capital Market. Zensitive provides project management, quality control, and supervision of fit-out work to transform interior spaces into functional environments. Cohen & Co. was enlisted as book-running manager for new blank check registrants Danneskjold and Galt Acquisition, Inflection Point Acquisition VIII, and Southport Acquisition II. Danneskjold and Galt intend to seek targets in the fintech and AI sectors, while Southport II will focus solely on AI companies. New York City-headquartered SPACs Eaglesky Acquisition, Lucens Capital Acquisition I, and Rainier Acquisition also registered. Lucens will target businesses based in, or whose revenues, operations, or strategic growth are linked to, Argentina. Rainier intends to pursue life sciences companies. The week’s SIC 6770 (Blank Checks) new public filers also included 1776 Acquisition, Gravity Acquisition, JATT III Acquisition, and Luminous Acquisition. Members of Gravity’s management team have significant ties to China, which may make it less attractive to certain non-Chinese combination partners. The sponsor of Luminous is an affiliate of sole book-running manager ARC Group Securities. Its management team has prior experience with 15 blank checks.
Withdrawals. No companies chose to withdraw their pending IPO registration statements last week.
The information reported in IPO Tracker is gathered using IPO Vital Signs, a Wolters Kluwer Regulatory U.S. database that includes all SEC registered IPOs, including REITs and those non-U.S. IPO filers seeking to list in the U.S. markets. IPO Vital Signs does not track closed-end funds, best efforts or non-underwritten deals, or IPO offerings for amounts less than $5 million.
Companies: ARC Group Securities Acquisition I; BOA Acquisition Corp. II; Attovia Therapeutics, Inc.; TCGX Acquisition Corp.; Braveheart Bio, Inc.; BlossomHill Therapeutics, Inc.; Latigo Biotherapeutics, Inc. Pinnacle Acquisition Corp.; Ticketplus Ltd.; OceanLight Acquisition Corp.; 1776 Acquisition Corp.; Luminous Acquisition; Gravity Acquisition Corp.; Rainier Acquisition Corp.; KiNRG, Inc.; Lucens Capital Acquisition Corp. I; Danneskjold and Galt Acquisition Co.; Eaglesky Acquisition Corp.; Inflection Point Acquisition Corp. VIII; JATT III Acquisition Corp.; Southport Acquisition Corp. II; Zensitive Holding Ltd.
IndustryNews: IPOs CorporateFinance FormsFilings SecuritiesOfferings